1. KYPROLIS® (carfilzomib) prescribing information, Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V2.2021. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed October 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. 3. Data on file, Amgen; 2015. 4. Moreau P, Joshua D, Chng W-J, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017;31:115-122. 5. Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27-38. 6. Data on file, Amgen; 2017. 7. Facon T, Niesvizky R, Weisel K, et al. Carfilzomib in relapsed or refractory multiple myeloma: frailty subgroup analysis from phase 3 ASPIRE and ENDEAVOR. Poster presented at: 17th International Myeloma Workshop; September 12-15, 2019; Boston, MA. 8. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328-e346. 9. Dimopoulos MA, Goldschmidt H, Niesvizky R, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327-1337.
All trademarks are the property of their respective owners.